SAN DIEGO, CA USA (Press Release) - April 11, 2014 - GenomeDx Biosciences announced today that two study abstracts for the company’s genomic tests for prostate and bladder cancers have been selected as “Best Posters in a Poster Session” by conference organizers at the 29th Annual European Association of Urology Congress.
The first poster presentation demonstrates the clinical validation of the Decipher® prostate cancer classifier for predicting treatment failure in men treated with post-surgery radiation therapy. The second poster presentation reports on the discovery and validation of a 15-marker genomic signature for predicting recurrence in high-risk bladder cancer.
The schedule for the poster presentations at EAU follows:
Session Title: “Improvement in prostate cancer biomarkers measurement”
Abstract Title: “Validation of a genomic classifier for predicting biochemical failure following post-operative radiation therapy in high-risk prostate cancer”
Date and Time: Saturday, April 12, 2014, 4:00 p.m. to 5:30 p.m. UTC
Abstract #: 205
Session Title: “Modern staging of urothelial carcinomas of the bladder and the upper tract: A new era has started”
Abstract Title: “Discovery and validation of a novel expression signature for predicting recurrence in high-risk bladder cancer post-cystectomy”
Date and Time: Monday, April 14, 2014, 12:15 p.m. to 1:45 p.m. UTC
Abstract #: 898
About GenomeDx Biosciences
GenomeDx Biosciences develops and commercializes genomic tests for prostate and other urologic cancers that impact treatment decision-making, improve patient outcomes and ultimately reduce healthcare costs. GenomeDx has developed the Decipher Prostate Cancer Classifier, the first and only commercially available genomic test that predicts the risk of developing metastatic prostate cancer independently of PSA and other conventional risk assessment tools. GenomeDx is based in San Diego, California and Vancouver, British Columbia. www.genomedx.com.
[ PRESS RELEASE ]